RDY 55.89 Dr. Reddy's Laboratories Ltd $RDY Hit a 52 week

New Post Public Reply Private Reply Replies (0) Message Board

Nov 14, 2014 at 2:37 PM

RDY 55.89 Dr. Reddy's Laboratories Ltd $RDY Hit a 52 week high of 56.22 Closing the day 09:45 at 55.89 -0.36 -0.64% With a day low of 55.70 and a total volume of 27,203.

RDY Recent Posts: http://investorshangout.com/Dr-Reddys-Laborat...RDY-52499/

RDY Dr. Reddy's Laboratories Ltd Recent Headline News

Sucampo-Takeda Sue Dr. Reddy's for Amitiza Patent Violation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 3:30PM CST
Sucampo Pharmaceuticals, Inc. (SCMP) and partner Takeda Pharmaceutical Company Limited filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Dr. Reddy's Laboratories (RDY).
JAZZ: 173.89 (+0.91), ARQL: 1.17 (-0.02), SCMP: 11.15 (+0.05), RDY: 55.95 (-0.30)

Dr. Reddy's cleared for generic Valcyte
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:34AM CST

ENDP: 66.60 (-0.50), RDY: 55.95 (-0.30)

Dr. Reddy's (RDY) Q2 Earnings Fall, Revenues Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 4:20PM CDT
Dr. Reddy's Laboratories (RDY) reported second-quarter fiscal 2015 earnings per American Depositary Share (ADS) of 54 cents, down 17% from the year-ago quarter.
MNK: 86.82 (-0.14), ACT: 244.21 (+2.58), MYL: 53.66 (-1.07), RDY: 55.95 (-0.30)

Dr. Reddy's Laboratories (RDY) Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 12:50AM CDT

RDY: 55.95 (-0.30)

Dr. Reddys ups revenues 7% in FQ2
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 12:43PM CDT

RDY: 55.95 (-0.30)

Dr. Reddy's FQ2 EPS of $0.54
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 5:55AM CDT

RDY: 55.95 (-0.30)

Dr. Reddy's Q2 and H1 FY15 Financial Results
Business Wire - Wed Oct 29, 5:41AM CDT
--Q2 FY15 EBITDA at Rs. 8.7 billion (24% of the revenues)
RDY: 55.95 (-0.30)

Dr. Reddy's Announces the Launch of Sirolimus Tablets, 1 mg and 2 mg
Business Wire - Tue Oct 28, 12:24PM CDT
Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Sirolimus Tablets 1 mg and 2 mg, a therapeutic equivalent generic version of RAPAMUNE(R) (Sirolimus) tablets in the US market on October 27, 2014, following the approval by the United States Food & Drug Administration (USFDA).
RDY: 55.95 (-0.30)

Dr. Reddy's reports on October 29
Seeking Alpha - at Seeking Alpha - Fri Oct 17, 6:09AM CDT

RDY: 55.95 (-0.30)

Dr. Reddy's to Release Q2 FY15 Results on October 29, 2014
Business Wire - Fri Oct 17, 4:38AM CDT
Dr. Reddy's Laboratories (NYSE: RDY) will announce results for the Second Quarter ended September 30, 2014 on Wednesday, October 29, 2014 after the Board Meeting. The results will be available on the Company's website www.drreddys.com.
RDY: 55.95 (-0.30)

Sucampo Enters into Settlement Agreement for Amitiza - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 4:50PM CDT
Sucampo Pharmaceuticals, Inc. (SCMP) has entered into a settlement agreement with Anchen and Par regarding a patent litigation related to Sucampo's Amitiza.
LCI: 46.77 (-1.51), SCMP: 11.15 (+0.05), RDY: 55.95 (-0.30)

Dr Reddys Laboratories Has Returned 20.3% Since SmarTrend Recommendation (RDY)
Comtex SmarTrend(R) - Wed Oct 08, 4:57PM CDT
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on June 26th, 2014 at $41.48. In approximately 3 months, Dr Reddys Laboratories has returned 20.35% as of today's recent price of $49.92.
RDY: 55.95 (-0.30)

Dr Reddys Laboratories Shares Up 26.0% Since SmarTrend's Buy Recommendation (RDY)
Comtex SmarTrend(R) - Wed Oct 01, 11:03AM CDT
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on June 26th, 2014 at $41.48. In approximately 3 months, Dr Reddys Laboratories has returned 25.96% as of today's recent price of $52.25.
RDY: 55.95 (-0.30)

Dr. Reddy's (RDY) Generic Xopenex Launched in the US - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 5:19PM CDT
Dr. Reddy's Laboratories Ltd. (RDY) has launched its generic version of Sunovion Pharmaceuticals Inc.???s Xopenex in the U.S.
SUPN: 8.48 (-0.01), MYL: 53.66 (-1.07), TEVA: 57.09 (-0.08), RDY: 55.95 (-0.30)

Uptrend Call Working As Dr Reddys Laboratories Stock Rises 26.6% (RDY)
Comtex SmarTrend(R) - Wed Sep 24, 9:40AM CDT
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on June 26th, 2014 at $41.48. In approximately 3 months, Dr Reddys Laboratories has returned 26.59% as of today's recent price of $52.51.
RDY: 55.95 (-0.30)

Dr. Reddy's unveils US FDA approved Levalbuterol Inhalation Solution, USP for oral inhalation only
M2 - Wed Sep 24, 7:03AM CDT
Pharmaceutical company Dr. Reddy's Laboratories (NYSE:RDY) reported on Wednesday the market availability of Levalbuterol Inhalation Solution, USP 0.31 mg /3 ml, 0.63 mg /3 ml, 1.25 mg / 3 ml Unit-Dose Vials in the US.
RDY: 55.95 (-0.30)

Dr. Reddy's Announces the Launch of LEVALBUTEROL INHALATION SOLUTION, USP
Business Wire - Wed Sep 24, 2:27AM CDT
Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Levalbuterol Inhalation Solution, USP 0.31 mg /3 mL, 0.63 mg /3 mL, 1.25 mg / 3 mL Unit-Dose Vials, a therapeutic equivalent generic version of XOPENEX(R) (levalbuterol hydrochloride) inhalation solution in the US market on September 23, 2014, approved by the United States Food & Drug Administration (USFDA).
RDY: 55.95 (-0.30)

17.9% Return Seen to Date on SmarTrend Dr Reddys Laboratories Call (RDY)
Comtex SmarTrend(R) - Tue Sep 09, 4:52PM CDT
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on June 26th, 2014 at $41.48. In approximately 3 months, Dr Reddys Laboratories has returned 17.91% as of today's recent price of $48.91.
RDY: 55.95 (-0.30)

Uptrend Call Working As Dr Reddys Laboratories Stock Rises 18.5% (RDY)
Comtex SmarTrend(R) - Tue Sep 02, 10:58AM CDT
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on June 26th, 2014 at $41.48. In approximately 2 months, Dr Reddys Laboratories has returned 18.47% as of today's recent price of $49.14.
RDY: 55.95 (-0.30)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Weifang's Cultural Resurgence: A Global Epigraphy Fest

A Historical Meltdown into Global Recognition Welcome to the ride where ancient stones talk and cultural borders vanish. We're diving into the beating heart of Weifang, a place you're probably hearing about now because the town's hosting a packed international media tour. And, for a change, this isn't just another tourist trap; it's a cultural adrenaline shot to the arm,...

Voter Events by Valley Community Healthcare Aim to Empower

Here's a game-changer for the community. Valley Community Healthcare (VCH) is stepping up, proving that healthcare doesn't just stick to check-ups and prescriptions. It's about the whole shebang—community empowerment included. This October, VCH is hosting two incredible voter events, collaborating with the Los Angeles County Registrar-Recorder's Mobile Voting Program....

Innventure Faces Major Lawsuit Over Misleading Investors

Missteps at Innventure: A Costly Lesson in Investor Trust The stock market is no stranger to drama, but Innventure's saga feels like a page ripped right out of a thriller novel. You’ve got accusations, alleged fabrications, and a swift drop in stock prices that’s left some investors shaking their heads. The company, nestled under the ticker NASDAQ:INV, finds itself...

Masimo's smartSET™ Revolutionizes Patient Monitoring

Breaking Ground in Patient Monitoring Let's dive into the gritty details behind Masimo's latest FDA-nod: the smartSET™ system. This gizmo ain't your ordinary pulse oximeter; it's a next-gen hand-holder for the medical world, poised to ride the AI wave straight into the clinic. They've cracked open a new way for clinicians to peek behind the curtain of patient vitals,...

Hyliion Class Action Deadline Nears for Investors

Potential Shockwaves for Hyliion Investors Investors are having a showdown with Hyliion (NYSE:HYLN) these days. With the looming October 27, 2026, deadline to jump into a securities class action, it seems Hyliion's latest escapade smells worse than a fish market on a hot day. We’ve got allegations here stronger than your uncle’s morning coffee. Understanding the Legal...

LG OLED evo W6: UAE Roadshow Starts with a Bang

They've done it again, folks. LG Electronics is out there kicking up a storm with their all-new OLED evo W6 True Wireless Wallpaper TV, and they're bringing the action straight to the UAE's doorsteps. Imagine taking a stroll and stumbling upon this technological marvel at some fancy spot like The Lotus Lounge at Anantara The Palm Dubai Resort. This ain't just a TV, it's a...

AEVEX Facing Class Action Deadline Amid Stock Turmoil

Investors are no strangers to the rough and tumble of stock markets, but things get downright messy when trust is shattered. That's the sorry saga unfolding with AEVEX, where shareholders are feeling the heat after a sharp nosedive in stock value. The clock is ticking to join the class action, and any AEVEX investor worth their salt should pay attention. Unraveling...